Given the FDA's April 2026 proposal with a comment period closing June 29, 2026, this a real question for anyone starting a multi-month compounded GLP-1 program right now
Both share stomach-heavy side effects: nausea, vomiting, diarrhea, constipation, injection-site reactions
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed weight management
The healing rationale is plausible, but there is no robust trial showing copper peptides improve transplant results, and a healing scalp is easily harmed
doi:10.1089/ACM.2006.12.857
The heightened GLP-1 levels observed after weight loss surgery may be attributed to reduced activity of dipeptidyl peptidase IV, the enzyme responsible for degrading GLP-1